Acumen Pharmaceuticals, Inc. ABOS
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) is a CNS/neurology/psychiatry drug developer. Its lead program, sabirnetug (ACU193), is in Phase 2 for Early Alzheimer's disease (MCI or mild dementia due to AD). Its next catalyst on record is sabirnetug (ALTITUDE-AD): Phase 2 top-line results (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: sabirnetug (ALTITUDE-AD) — Phase 2 top-line results (H2 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| sabirnetug (ACU193) IV - ALTITUDE-AD | Early Alzheimer's disease | antibody | Phase 2 |
| sabirnetug subcutaneous formulation | Alzheimer's disease | antibody | Phase 1 |
| ACU301 / ACU401 (Enhanced Brain Delivery, with JCR) | Alzheimer's disease | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.